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Abstract. 
 
The extracellular matrix glycosaminoglycan 
hyaluronan (HA) is an abundant component of skin 
and mesenchymal tissues where it facilitates cell migra-
tion during wound healing, inflammation, and em-
bryonic morphogenesis. Both during normal tissue
homeostasis and particularly after tissue injury, HA is 
mobilized from these sites through lymphatic vessels to 
the lymph nodes where it is degraded before entering 
the circulation for rapid uptake by the liver. Currently, 
however, the identities of HA binding molecules which 
control this pathway are unknown. Here we describe 
the first such molecule, LYVE-1, which we have identi-
fied as a major receptor for HA on the lymph vessel 
wall. The deduced amino acid sequence of LYVE-1 
predicts a 322-residue type I integral membrane 
polypeptide 41% similar to the CD44 HA receptor with 
a 212-residue extracellular domain containing a single 
Link module the prototypic HA binding domain of the 
Link protein superfamily. Like CD44, the LYVE-1 
molecule binds both soluble and immobilized HA. 
However, unlike CD44, the LYVE-1 molecule colocal-
izes with HA on the luminal face of the lymph vessel 
wall and is completely absent from blood vessels. 
Hence, LYVE-1 is the first lymph-specific HA receptor 
to be characterized and is a uniquely powerful marker 
for lymph vessels themselves.
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H
 
YALURONAN
 
 (HA),
 
1
 
 a linear polymer of (1-
 
b
 
-4)
 
D
 
-glucuronic acid (1-
 
b
 
-3) 
 
N
 
-acetyl-
 
D
 
-glucosamine,
is a large glycosaminoglycan found in the tissue
matrix and body fluids of all vertebrates which plays a fun-
damental role in regulating cell migration and differentia-
tion (26). This role is first apparent during development,
when changes in the levels of matrix HA induce condensa-
tion of mesenchymal cells and lead to the onset of chon-
drogenesis and myogenesis (reviewed in 19). In later life,
HA facilitates cell migration in processes such as wound
healing and inflammation by forming a pericellular matrix
surrounding fibroblasts and epithelial cells, reducing the
level of intercellular adhesion (20Ð22). The critical impor-
tance of HA in all of these roles is underlined by the ob-
servation that deletion of HA synthases in knockout mice
results in early death of the embryo (31).
The largest concentrations of HA are found within the
skin and musculo-skeletal system which account for 
 
.
 
50%
of total body HA. Here the rate of HA turnover is rapid
(
 
t
 
1/2
 
 0.5 d) by comparison with other extracellular matrix
components (26). Surprisingly, most degradation does not
occur within the skin itself; rather HA is transported
through the lymphatic system to distant lymph nodes
where 
 
.
 
90% of the glycosaminoglycan in afferent lymph
is degraded or reenters the circulation to be rapidly en-
docytosed by liver endothelial HA receptors (11, 12).
Hence, the lymphatic vessels are a major conduit for HA
transport from tissues such as the skin and intestine, where
flux measurements indicate they can remove as much as
10% of the total HA content within a 24-h period (36).
This turnover can be further increased after either tissue
injury or sepsis. Yet why HA should require transport
through the lymphatics is not presently understood and lit-
tle or nothing is known about the nature of any HA-bind-
ing molecules involved.
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man umbilical vein endothelial cells; LEC, liver endothelial cell; LYVE-1,
lymphatic vessel endothelial HA receptor 1; RHAMM, receptor for hy-
aluronan mediated motility; vWF, von Willebrand factor. 
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The majority of HA-binding proteins within the tissues
belong to the Link protein superfamily. Members of this
superfamily contain a conserved disulfide linked domain
of 
 
z
 
100 amino acid residues termed the Link module,
which binds the minimal recognition unit HA
 
6Ð8
 
 and
whose three-dimensional structure resembles the sugar-
binding domain of C-type lectins. Other superfamily mem-
bers in addition to the Link protein (34) include the large
matrix proteoglycans Aggrecan (9), Versican (61), and
Brevican (58), the tumor necrosis factorÐinducible protein
TSG-6 (28), and a single cell surface HA receptor, the
CD44 molecule (1, 40). CD44 is widely expressed on epi-
thelial, mesenchymal, and lymphoid cells, where it is
thought to constitute the major receptor for HA (reviewed
in 29). Interactions between CD44 and HA are implicated
in several diverse functions including the maintenance of
tissue structure within the epithelia (57), the extravasation
of lymphocytes through inflamed vascular endothelium (8,
33), and the hematogenous dissemination of tumor cells
(46, 47). The only other HA receptors characterized to
date are RHAMM (receptor for HA-mediated motility), a
58-kD intracellular protein expressed transiently on the
surface of transformed lymphocytes (15, 53), the cation-
dependent liver endothelial cell (LEC) receptors responsi-
ble for the clearance of HA from the serum (59, 60), and
the nuclear protein cdc37 (14). To date, however, there is
no specific evidence that either CD44, RHAMM, or the
LEC HA receptors are involved in the sequestration or
transport of HA by lymphatic vessels, or in its uptake or
degradation within the lymph nodes. Indeed, deletion of
the CD44 gene in knockout mice produced no significant
abnormalities, and resulted in no significant disruption of
lymphatic function (43). Hence the identities of HA recep-
tors involved in lymphatic HA homeostasis are completely
unknown and we understand little about the regulation of
this important physiological process.
Here we present the first identification of an HA recep-
tor that is almost exclusively expressed on lymph vessels
and is absent from blood vessels. This novel receptor
which we have named LYVE-1 is a homologue of the
CD44 HA receptor and a new member of the Link protein
superfamily. We present evidence that LYVE-1 sequesters
HA on lymph vessel endothelium in vivo and highlight the
significance of this novel receptor in further defining the
structure and function of the lymphatic system.
 
Materials and Methods
 
Cells, Antibodies, Chemicals, and Ig Fusion Proteins
 
Human umbilical vein endothelial cells (HUVEC) were kindly donated
by Dr. Sue Adams (Molecular Parasitology Group, University of Oxford)
and used at the third passage. mAbs to human CD31 (JC70), CD34
(QBEND 10), and von Willebrand factor (vWF, F8/86) were kindly do-
nated by Dr. David Mason (Department of Cellular Science, University of
Oxford). Texas redÐconjugated goat antiÐrabbit IgG and fluorescein-con-
jugated goat antiÐmouse IgG reagents were obtained from Southern Bio-
technologies. Biotinylated HA-binding complex (bHABC) was purified
from bovine articular cartilage by extraction with 4 M guanidine-HCl and
biotinylated as described previously (48). Biotin-LC-hydrazide was ob-
tained from Pierce Chemical Co., and high molecular weight HA (rooster
comb) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC)
were from Sigma Chemical Co. Soluble Ig Fc (fragment-complement
binding) fusion proteins corresponding to the extracellular domains of
 
CD44 hematopoietic form (residues 1Ð200, CD44H Fc; see refs. 1, 37),
ICAM-2 (complete extracellular domain, ICAM-2 Fc), and CD33 (com-
plete extracellular domain, CD33 Fc) fused to the hinge, CH2, and CH3
domains of human IgG
 
1 
 
were donated, respectively, by Dr. Kelly Bennett
(Bristol-Myers Squibb, Seattle, WA), Dr. Sue Adams (see above), and Dr.
Regis Doyonnas (MRC Molecular Haematology Unit, Institute of Molec-
ular Medicine, University of Oxford). A soluble truncated form of
CD44H (CD44
 
158his
 
) comprising residues 1Ð158 of the ectodomain was ex-
pressed in 
 
Escherichia coli
 
 and refolded from urea-solubilized inclusion
bodies (3). Details of the CD44
 
158his
 
 protein which displays similar HA
binding to CD44H Fc have been published recently (3).
 
Cloning and Identification of the LYVE-1
Receptor cDNA
 
A commercial cDNA database (Human Genome Sciences, The Institute
for Genome Research) of 
 
.
 
10
 
6
 
 expression sequence tags (ESTs) obtained
by random DNA sequencing of clones within 700 different human cDNA
libraries was screened for ESTs bearing significant homology to the CD44
HA receptor using the program BlastSearch (Genetics Computer Group).
Several overlapping ESTs with translated amino acid sequences that were
at least 30% identical to that of full-length CD44 were identified in cDNA
libraries constructed from tissues including umbilical vein, placenta, fetal
liver, adipose tissue, lung, heart, prostate, embryo, spinal cord, bone mar-
row, bone, and ovarian tumor. The LYVE-1 EST described here was iso-
lated from a HUVEC cDNA library, subcloned into the plasmid vector
pBluescript, and sequenced in its entirety.
 
Northern Blot Hybridization
 
For Northern blot analysis, multiple tissue RNA blots (2 
 
m
 
g polyade-
nylated RNA per lane) were purchased from Clontech and hybridized
(42
 
8
 
C, 50% formamide, 6
 
3
 
 SSC) to a full-length LYVE-1 double-
stranded DNA probe labeled with [
 
32
 
P]dCTP by random hexamer-prim-
ing (Rediprime DNA labeling system; Amersham International plc).
Blots were washed at high stringency (0.1
 
3
 
 SSC, 60
 
8
 
C, 15 min) before ex-
posure to Kodak X-Omat RP x-ray film.
 
RT-PCR
 
For the detection of LYVE-1 and CD44 mRNAs in different cell lines, to-
tal RNA was isolated by extraction with guanidinium thiocyanate/sodium
acetate, pH 4.0, and ethanol precipitation followed by first-strand cDNA
synthesis using reverse transcriptase, and PCR using appropriate LYVE-1
or CD44 primers.
First-strand cDNA syntheses were carried out by oligo-dT priming in
50-
 
m
 
l reactions containing 5 
 
m
 
g total RNA, 0.5 
 
m
 
M dNTPs, 0.1 M Tris-
HCl, pH 8.3, and 2.5 mU AMV reverse transcriptase for 3 h at 42
 
8
 
C. Sam-
ples (1 
 
m
 
l) of the final products were then committed to 50-
 
m
 
l PCR reac-
tions (94
 
8
 
C, 1 min; 55
 
8
 
C, 1 min; 72
 
8
 
C, 1 min; 40 cycles) containing 10 mM
Tris-HCl, pH 8.3, 50 mM KCl, 2.5 mM MgCl
 
2
 
, 1 mM dNTPs, 1 U 
 
Taq
 
DNA polymerase, and the LYVE-1 primers LYVE-1F Hind/LYVE-1R
Bam (see below), or the CD44 primers AMP1 (TCCCAGTATGACA-
CATATTGC) and AMP2 (CCAAGATGATCAGCCATTCTGG). The
integrity of the cDNA and input RNA was confirmed by PCR with
the glyceraldehyde-3-phosphate dehydrogenase primers G3PF (TGGT-
CGTATTGGGCGCCTGG) and G3PR (CCAAATTCGTTGTCAT-
ACCAGG). Products were electrophoresed on 1.25% agarose gels,
transferred to charged nylon membranes (Hybond N; Amersham Interna-
tional plc), and hybridized with 
 
32
 
P-end-labeled oligonucleotide probes to
detect either LYVE-1 (CGCGGATCCCCATAAAAACTTCTGTGA-
CAC) or CD44 (TGTACATCAGTCACAGACCTGCA). Blots were
washed at 55
 
8
 
C in 6
 
3
 
 SSC for 10 min before autoradiography.
 
Preparation of Full-Length LYVE-1 cDNA in pRcCMV 
and Transient Transfection of COS 1 Cells
 
For cell surface expression of full-length LYVE-1 molecules, the entire
LYVE-1 coding sequence together with 11 bp of 5
 
9
 
 untranslated region
and 40 bp of 3
 
9
 
 untranslated region was reamplified (94
 
8
 
C, 1 min; 55
 
8
 
C, 1
min; and 72
 
8
 
C, 1 min, 30 cycles) from the original pBluescript clone (see
above) with the primers LYVE-1 F Hind (CGCG
 
AAGCTT
 
GGGTAG-
GCACGATGGCCAG) and LYVE-1 R Xba (GC
 
TCTAGA
 
GCCTCAG-
GTGTGTCTCCTC) using 
 
Pyrococcus furiosus
 
 (Pfu) DNA polymerase,
and ligated into HindIII/XbaI cut pRcCMV. The pRcCMV construct was 
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then used to transiently transfect COS 1 cells using DEAE dextran and
chloroquine as described previously (17).
 
Expression of LYVE-1 as a Soluble IgFc Fusion Protein
 
A 684-bp LYVE-1 fragment encoding the predicted NH
 
2
 
-terminal leader
and extracellular domain, truncating at Gly 232, was amplified (94
 
8
 
C 1
min; 60
 
8
 
C 5 min; and 72
 
8
 
C 10 min, 25 cycles) from the full-length LYVE-1
cDNA clone in pBluescript using Pfu polymerase and the primers LYVE-
1F Hind (see above for sequence) and LYVE-1 R Bam (CGC
 
GGATC-
C
 
CCAGCAGCTTCATTCTTGAATG). After digestion with HindIII
and BamH1, the product was cloned into BamH1/HindIII cut IgFc vector
to yield a construct encoding amino acid residues 1Ð232 of the LYVE-1 se-
quence, fused at the COOH terminus with the 234-residue hinge, CH2,
and CH3 region of human IgG
 
1
 
 (1). The absence of polymerase-induced
errors was confirmed by sequencing the resulting construct on both
strands. For expression, the LYVE-1 cDNA was transiently transfected
into SV-40Ðtransformed African green monkey kidney cells (COS 1) us-
ing DEAE dextran. After 72 h, culture supernatants were collected, sup-
plemented with 0.1 M Tris-HCl, pH 8.0, and the fusion protein purified by
protein AÐSepharose affinity chromatography. Purity was assessed by
SDS-PAGE analysis under both reducing and nonreducing conditions,
and by Western blot analysis with peroxidase-conjugated antiÐhuman
IgGFc antibody.
 
Western Blotting/Biosynthetic Labeling
 
For detection of LYVE-1 protein expressed in transfected COS 1 cell ly-
sates, these were boiled in SDS-PAGE sample buffer, electrophoresed on
10% polyacrylamide SDS-PAGE gels, and transferred to nitrocellulose
membranes (Hybond super; Amersham International plc) using a semi-
dry transfer apparatus (Hoefer). Blots were incubated with LYVE-1 poly-
clonal serum (1:100 dilution in PBS, pH 7.5, 5% dried milk powder, 0.1%
Tween 20), and developed with peroxidase-conjugated antiÐrabbit Ig us-
ing chemiluminescent detection (ECL kit; Amersham International plc).
For biosynthetic labeling of LYVE-1 Fc fusion proteins, transiently
transfected COS 1 cells were cultured (24 h, 37
 
8
 
C) in RPMI supplemented
with 100 
 
m
 
Ci/ml [
 
35
 
S]methionine/cysteine (Amersham International plc)
followed by absorption of the labeled fusion proteins from the super-
natants on protein AÐSepharose beads. Beads were then boiled in
SDS-PAGE sample buffer and electrophoresed on 10% polyacrylamide
SDS-PAGE gels. After electrophoresis, the gels were fixed, stained with
Coomassie blue, and impregnated with AMPLIFY (Amersham Interna-
tional plc), before drying and exposing to Kodak X-Omat x-ray film at
 
2
 
70
 
8
 
C.
 
HA-binding Assays
 
Binding to Immobilized HA. 
 
Binding of LYVE-1 IgFc fusion protein to im-
mobilized HA was measured in a 96-well microtiter plate ELISA assay. In
brief, microtiter plates (Nunc Maxisorp) were coated with HA (purified
from rooster comb; Sigma) at a concentration of 2 mg/ml in coating buffer
(15 mM sodium carbonate and 34 mM sodium bicarbonate, pH 9.3). After
overnight incubation at 25
 
8
 
C, blocking (2 h) in PBS, pH 7.5, 0.25% (wt/
vol) BSA, 0.05% (wt/vol) Tween 20, and washing (three times, PBS, pH
7.5), plates were incubated with purified LYVE-1 IgFc or CD44H Fc, or
with the control proteins ICAM-2 Fc or CD33 Fc (15Ð500 ng/well) for 1 h
at 25
 
8
 
C. After removal of unbound protein by washing (three times) with
PBS, bound fusion protein was detected by successive (1 h, 25
 
8
 
C) incuba-
tion with horseradish peroxidaseÐconjugated antiÐhuman IgG
 
1
 
 antibody.
Reactions were developed by the addition of 
 
O
 
-phenylenediamine sub-
strate and the absorbance measured at 490 nm in a Bio-Rad microplate
reader. To determine the binding specificity of LYVE-1 for other gly-
cosaminoglycans, the standard assay was modified to include either free
chondroitin-4 sulfate, chondroitin-6 sulfate, or heparin (1.5Ð200 
 
m
 
g/ml) as
competitor during the primary incubation step.
 
Binding to Soluble HA. 
 
For binding assays with soluble HA, this was
first biotinylated by a modification of the method of Yu and Toole (33). In
brief, high molecular weight HA (5 mg/ml) in 0.1 M MES, pH 5.5, was
derivatized with biotin-LC-hydrazide (1 mM) in the presence of 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide (EDAC, 0.16 mg/ml) in 1-ml
stirred reactions overnight at room temperature, followed by dialysis
against PBS, pH 7.5, to remove free biotin.
To perform the standard binding assay, microtiter plates were coated
with LYVE-1 Fc, CD44H Fc, or the control fusion proteins CD33 Fc or
ICAM-2 Fc (1.25Ð10 
 
m
 
g/ml, 1 h, 25
 
8
 
C) washed (three times) to remove un-
bound material, and incubated with biotinylated HA (5 
 
m
 
g/ml) for a fur-
ther 1 h. Bound HA was then detected by incubation with horseradish
peroxidaseÐconjugated streptavidin (Sigma) and 
 
O
 
-phenylenediamine
substrate. Absorbances were measured at 490 nm in a Bio-Rad microplate
reader as described above.
 
Sandwich Assay for Binding to Preformed HA Receptor Complexes. 
 
To
measure binding of LYVE-1 to HA presented as a complex with CD44,
microtiter plates were coated with bacterially expressed CD44
 
158his
 
 (5 
 
m
 
g/ml),
before successive incubations with HA (250 
 
m
 
g/ml) and either LYVE-1 (5
 
m
 
g/ml) or CD33 Fc (5 
 
m
 
g/ml, negative control), followed by detection with
peroxidase-conjugated antiÐhuman IgFc (see above). To measure binding
of CD44 to HA presented as a complex with LYVE-1, microtiter plates
were coated with either LYVE-1 Fc or CD33 Fc (negative control), before
successive incubations with HA (250 
 
m
 
g/ml) and CD44H Fc (5 
 
m
 
g/ml) and
detection with the peroxidase-conjugated CD44 mAb A3D8 (1 
 
m
 
g/ml).
 
Production of LYVE-1 Polyclonal Serum
 
For the production of polyclonal antisera, rabbits were immunized with
purified LYVE-1 Fc fusion protein (100 
 
m
 
g) in complete FreundÕs adju-
vant, followed by three consecutive boosts (50 
 
m
 
g) in incomplete adjuvant,
at intervals of 4 wk. Sera were then tested for reactivity with LYVE-1 Fc
or with the irrelevant receptor-globulin controls CD33 Fc or ICAM-2 Fc,
immobilized to 96-well microtiter dishes using an ELISA assay detected
with peroxidase-conjugated goat antiÐrabbit IgG and 
 
O
 
-phenylenedi-
amine. Antibodies reactive with the human IgG portion of the immuniz-
ing antigen were depleted by preabsorption on columns of human IgG
Sepharose.
 
Immunoperoxidase and Immunofluorescent Antibody 
Staining of Cells and Tissues
 
For immunoperoxidase staining, normal human tissue samples were ob-
tained from the Department of Histopathology, Oxford Radcliffe Hospi-
tal, as paraffin-embedded sections on silanized glass microscope slides.
Slides were dewaxed and rehydrated by successive incubation in Citro-
clear (5 min), 100% ethanol (5 min), 70% ethanol (5 min), and water fol-
lowed by microwave treatment (700 W, 8 min) and incubation (30 min,
25
 
8
 
C) with 1:100 diluted LYVE-1 serum in PBS, 5% human serum, 0.1%
azide. Antigen was subsequently detected by incubation (30 min, 25
 
8
 
C)
with an antiÐrabbit Ig peroxidase conjugate, and diaminobenzidine (Envi-
sion kit; DAKO), before counterstaining (30 s) with hematoxylin and
eosin.
For standard single/double immunofluorescent staining, tissue sections
on glass microscope slides were dewaxed and rehydrated as described
above before incubation (30 min, 5
 
8
 
C) with 1:100 diluted LYVE-1 serum
in PBS, 5% human serum, 0.1% azide, either alone or in combination with
1:2 diluted CD31, CD34, or vWF hybridoma supernatants, or with CD44
mAb (10 
 
m
 
g/ml). After washing (twice) to remove unbound antibodies,
samples were then stained (30 min, 5
 
8
 
C) with 1:25 diluted FITC-conju-
gated goat antiÐrabbit Ig (to detect LYVE-1), either alone or in combina-
tion with 1Ð50 diluted Texas redÐconjugated goat antiÐrabbit Ig. Samples
were fixed in 2% (wt/vol) formaldehyde and viewed under a Zeiss Ax-
ioskop fluorescence microscope using epifluorescent illumination.
Staining for HA and colocalization with LYVE-1 receptor was carried
out using complexes of biotinylated bovine aggrecan G1 domain and bo-
vine link protein as described previously (48). In brief, dewaxed and rehy-
drated tissue sections on glass microscope slides were blocked (30 min,
room temperature) in PBS, pH 7.5, containing 50 mM glycine and 1% (wt/
vol) fat-free milk powder, before incubation (overnight, 5
 
8
 
C) with
bHABC (5 
 
m
 
g/ml) with or without LYVE-1 serum (1:100 dilution) in 0.1 M
sodium phosphate buffer, pH 7.4, supplemented with 1% BSA. After
washing to remove unbound reagents, the sections were incubated (1 h,
room temperature) with a mixture of Texas redÐlabeled antiÐrabbit Ig and
FITC-labeled avidin (Vector Laboratories, Inc.), diluted 1:50 and 1:500,
respectively, in PBS, pH 7.5. Slides were mounted in Vectashield (Vector
Laboratories, Inc.) for immunofluorescence microscopy.
 
Results
 
Identification of a Novel HA Receptor LYVE-1
 
To identify new HA receptors we searched recent data-
bases of ESTs for cDNAs homologous to the CD44 mole- 
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cule, currently thought to be the primary HA receptor on
mammalian cells. A homology search of the combined Hu-
man Genome Sciences/TIGR EST databases with the
amino acid sequence of full-length CD44H using the
BLAST program identified a number of ESTs with pre-
dicted amino acid sequences 
 
.
 
30% similar to CD44. 59
identical ESTs were identified in libraries prepared from
fetal tissues including liver, spleen, brain, and heart; adult
human placenta, bone marrow, lung, and spinal cord; glio-
blastoma, ovarian, and bone tumor; and HUVEC. The
2,313-bp EST from HUVEC which we have termed
LYVE-1 (lymphatic vessel endothelial HA receptor) was
subjected to complete nucleotide sequencing. Translation
of the LYVE-1 cDNA (Fig. 1 A) revealed a large (966 bp)
open reading frame starting with a Kozak (24) consensus
ATG initiation codon at position 91 and terminating with
the TAG stop codon at position 1057. The deduced amino
acid sequence encodes a 322-residue polypeptide with the
features characteristic of a type I integral membrane gly-
coprotein. These are: a sequence of 26 largely hydropho-
bic residues at the NH
 
2
 
 terminus most likely comprising
the leader peptide; a hydrophilic sequence of 212 amino
acids containing seven cysteine residues, a serine/threo-
nine-rich region (residues 145Ð216) and two motifs for
N-linked glycosylation (NFT and NSS, centered on resi-
dues 54 and 131, respectively) corresponding to an extra-
cellular domain; a sequence of 21 hydrophobic residues
immediately followed by the dibasic motif KR and a
highly charged stretch of 63 residues predicted to form the
transmembrane anchor and cytoplasmic tail, respectively
(Fig. 1 A). The predicted transmembrane anchor is also
apparent in Kyte-Doolittle (25) and Goldman hydropathy
plots of the deduced amino acid sequence (Fig. 1 B). The
position of the mature NH
 
2
 
 terminus is predicted to be Ala
27 based on the 
 
2
 
3 
 
1
 
1 rule proposed by Von Heijne (56).
 
Similarities between the Link Modules in LYVE-1
and CD44
 
Alignment of the LYVE-1 amino acid sequence with that
of the human CD44 HA receptor (Fig. 2) illustrates the
degree of homology between the two molecules which
Figure 1. Nucleotide sequence and derived
amino acid sequence of LYVE-1, a novel human
HA receptor. A shows the complete nucleotide
and derived amino acid sequence for the 2,313-
bp LYVE-1 cDNA clone in pBluescript. A
cleavable NH2-terminal leader predicted using
the 23 11 rule (56) and a probable transmem-
brane anchor are underlined. The positions of
two putative N-glycosylation sites (N X S/T) are
boxed. The sequence predicts a 322Ðamino acid
residue polypeptide with a 26-residue leader
peptide, a 21-residue hydrophobic membrane
anchor, and a 63-residue cytoplasmic tail. B de-
picts Kyte-Doolittle (solid line) and Goldman
(stippled line) hydropathy plots of the derived
amino acid sequence, both of which confirm the
position of the predicted hydrophobic trans-
membrane anchor. These sequence data are
available from GenBank under accession num-
ber AF118108. 
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have an overall similarity of 41%. Closer inspection re-
veals the region of maximal homology (57% similarity,
38% identity) to be contained within the area encompass-
ing the extended CD44 Link domain and the correspond-
ing region (residues 36Ð139) in the LYVE-1 sequence (Fig.
2 A). The location of the putative Link module in LYVE-1
is marked by four central cysteine residues (Cys 61, 85,
106, and 128), whose spacing (C1 - X
 
23 
 
- C2 - X
 
20 
 
- C3 - X
 
20 
 
-
C4) is almost identical in CD44, and whose intervening se-
quences share 57% similarity. This similarity rises to 68%
(57% identity) between C2 (Cys 85) and C3 (Cys 106).
These four cysteine residues are conserved in all members
of the Link superfamily where they form essential disul-
fide bridges that stabilize the HA-binding domain, a struc-
ture comprising two 
 
a
 
 helices and two antiÐparallel 
 
b
 
sheets surrounding a large hydrophobic core (23). Inter-
estingly the two additional cysteine residues Cys 31 and
Cys 133 that uniquely flank the CD44 Link module (13,
45) are also present at appropriately conserved locations
in the LYVE-1 sequence (Cys 36 and Cys 139, Fig. 2 A).
Downstream of the Link module, however, the region cor-
responding to the membrane proximal domain of LYVE-1
shows little similarity to CD44, with the exception of a
moderately high proportion of serine and threonine resi-
dues (37% within residues 145Ð216).
The presence of the LYVE-1 Link module is more
clearly illustrated by sequence alignments with other hu-
man Link superfamily members including the cartilage
matrix proteins Aggrecan, Versican, and Link protein it-
self, each of which contain tandem repeats of the Link ho-
mology unit (Fig. 2 B). A novel feature apparent from
these alignments is that LYVE-1 and CD44 appear to
define a subgroup within the Link superfamily. These
findings suggest the divergence of the cell surface HA re-
ceptors as a separate branch from the HA-binding extra-
cellular matrix proteins during evolution.
More detailed comparisons of individual amino acid
residues within the putative HA-binding regions of the
LYVE-1 and CD44 Link modules reveal a number of dif-
ferences. For example, of the nine key residues identified
by site directed mutagenesis (2, 37) as critical for HA bind-
ing within the human CD44 Link domain, Lys 38 
 
1
 
 68,
Arg 41 
 
1
 
 78, Tyr 42, 79, 
 
1
 
 105, and Asp 100 
 
1
 
 101, only
three of these, Lys 38, Tyr 79, and Asp 100 are conserved
within the LYVE-1 molecule (residues 46, 87, and 109, re-
spectively, Fig. 2 A). Furthermore, the peripheral cluster
of basic amino acids located downstream of the Link mod-
ule in CD44, which includes Arg 158 and Lys 162 (Fig. 2
A) previously shown to be important for HA binding (37),
is not conserved in the LYVE-1 sequence. Hence, despite
overall similarities in Link module sequences, the specific
residues involved in the predicted LYVE-1Ðcarbohydrate
interaction are likely to be different from those in the
CD44 molecule.
 
The LYVE-1 Receptor Is Expressed on the Cell Surface
 
To confirm the identification of the LYVE-1 molecule as
an integral membrane glycoprotein, COS 1 fibroblasts
were transfected with LYVE-1 cDNA and stained with
polyclonal LYVE-1 antibodies for immunofluorescence
microscopy. The specificity of the LYVE-1 serum is char-
acterized in detail below. As shown by the results in Fig. 3
A, the transfectants displayed intense surface staining.
Western blotting of the LYVE-1 transfected COS cells us-
ing a polyclonal serum generated against soluble LYVE-1
revealed a major band which migrated with an apparent
molecular mass of 60 kD, and which was absent from
mock transfected cells. The discrepancy between the ex-
perimentally observed value and the size predicted from
the primary sequence (35,158 D) is largely due to glycosy-
lation, since treatment with either N-glycanase or O-glyca-
nase/neuraminidase reduced the molecular mass by 
 
z
 
20
kD (not shown).
Figure 2. Comparison of the LYVE-1 receptor Link module with
other Link superfamily members. In A, the derived amino acid
sequence of LYVE-1 (top line) is shown aligned with that of the
full-length human CD44 cDNA (bottom line) using the GCG
program GAP. Positions where amino acid residues are identical
are depicted with a line; semiconservative and conservative dif-
ferences are depicted with one or two dots, respectively. The two
sequences have an overall similarity of 41% and a similarity of
57% within the immediate Link homology unit (LYVE-1 resi-
dues 61Ð128). B shows a Prettyplot (GCG) comparison of se-
quence encompassing the ÒLink modulesÓ (HA-binding do-
mains) from LYVE-1 (corresponding to residues 40Ð138 in A),
human CD44, the soluble human tumor necrosis factorÐinducible
TSG-6 molecule, and both tandem repeats (Links 1 and 2) of hu-
man Aggrecan, human Versican, and human Cartilage Link pro-
tein. 
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LYVE-1 Binds Both Immobilized and Soluble HA
To confirm the presence of a functional HA-binding do-
main in the LYVE-1 receptor, we expressed the extracel-
lular domain with its own NH2-terminal leader (residues
1Ð232) as a soluble fusion protein with the hinge, CH2,
and CH3 domains of human IgG1 (total length 440 resi-
dues). The purified protein migrated as a single 80-kD
band on SDS-PAGE, similar to a CD44H Fc fusion pro-
tein (total length 434 residues, Fig. 4 A). The discrepancy
with the 46,900-D molecular mass predicted from the ma-
ture 440 residue primary sequence again is largely due to
N- and O-glycosylation of the LYVE-1 core polypeptide
(see above).
Comparison of LYVE-1 Fc with CD44 Fc in a microtiter
plate glycosaminoglycan binding assay (Fig. 4, B and C)
revealed that LYVE-1 binds immobilized HA in a concen-
tration-dependent manner that is similar if not identical to
CD44. In contrast, neither of the two control fusion pro-
teins CD33 Fc or ICAM-2 Fc displayed any significant
binding over this range (0.25Ð10 mg/ml). The specificity of
the LYVE-1 HA interaction was demonstrated by compe-
tition with free glycosaminoglycans, which showed that
neither chondroitin-4-SO4, chondroitin-6-SO4, nor hepa-
ran sulfate blocked binding even at concentrations up to
200 mg/ml (Fig. 4 C). In contrast the LYVE-1 HA interac-
tion was extremely sensitive to inhibition by free HA (IC50
z3 mg/ml). This indicates that LYVE-1 has a much higher
specificity for glycosaminoglycan binding than either
CD44 or the cation-dependent liver endothelial receptors.
Importantly, this also distinguishes LYVE-1 from the
lymph node receptors involved in the uptake and degrada-
tion of lymph fluid HA, since these are blocked by chon-
droitin sulfate and chondroitin sulfate proteoglycans (54).
LYVE-1 Fc also bound soluble high molecular mass HA
in a concentration-dependent fashion (Fig. 4 D), although
the binding capacity decreased dramatically with increas-
ing levels of HA biotinylation (data not shown), a feature
that was not observed with CD44. This latter result sug-
gests there is a significant difference in the size or geome-
try of the HA-binding surface within these two receptors.
LYVE-1 mRNA Has a Restricted Pattern of
Tissue Expression
Expression of the LYVE-1 gene in vivo was investigated
by Northern blot hybridization to poly(A)1 RNAs pre-
pared from a range of human tissues (Fig. 5). Two major
bands of z2 and 2.6 kb were abundant in spleen, lymph
node, heart, lung, and fetal liver RNA and to a lesser de-
gree in appendix, bone marrow, placenta, muscle, and
adult liver RNA. These were largely if not completely ab-
sent from peripheral blood lymphocytes, thymus, brain,
kidney, and pancreas RNA. In addition, minor bands of
6Ð7 kb were detected to a variable extent in spleen, lymph
node, fetal liver, heart, lung, and muscle. The 2.6-kb band
Figure 3. Cell surface expression of LYVE-1 receptor on transfected COS cells. In A, COS 1 cells were transiently transfected with ei-
ther full-length LYVE-1 cDNA in the expression vector pRcCMV (a and b), or with a control empty pRcCMV vector (c and d) using
DEAE dextran followed by surface immunofluorescent staining with rabbit polyclonal LYVE-1 antiserum (1:100 dilution) and FITC
goat antiÐrabbit IgG. In B, control and LYVE-1 transfected COS cells were electrophoresed on a 10% polyacrylamide SDS-PAGE gel,
transferred to nitrocellulose, and Western blotted with LYVE-1 antiserum and peroxidase-conjugated goat antiÐrabbit IgG (see Mate-
rials and Methods). Samples were control transfected COS (lane 1) and LYVE-1 transfected COS (lane 2). The positions and sizes in ki-
lodaltons of the molecular mass calibration markers myosin (205 kD), b-galactosidase (116 kD), phosphorylase b (97 kD), BSA (66 kD),
ovalbumin (45 kD), and carbonic anhydrase (29 kD) are indicated on the left.Banerji et al. Lymph Vessel Hyaluronan Receptor 795
is predicted to correspond to the LYVE-1 transcript
shown in Fig. 1, whereas the 2-kb band likely represents a
transcript that is polyadenylated on one or other of the
consensus AATAAA motifs at positions 1819 and 1905
within the 39 untranslated region (see Fig. 1). The minor
6Ð7-kb bands have not yet been characterized. Hence it is
possible they represent alternatively spliced LYVE-1 tran-
scripts.
Intriguingly, RT-PCR analyses (Fig. 6) of individual cell
lines derived from lymphocytes, myeloid cells, monocytes,
microvascular endothelial cells, and fibroblasts yielded no
products in any cell type with the exception of late passage
HUVEC, and placental tissue, used as a positive control.
In contrast, each cell line yielded abundant PCR products
when amplified with primers to CD44, or the housekeep-
ing gene glyceraldehyde-3-phosphate dehydrogenase. These
results suggested an unusually specific pattern of tissue ex-
pression for LYVE-1 that was clearly distinct from that of
the CD44 molecule.
The LYVE-1 Molecule Is Present on the Walls of 
Lymphatic Vessels
To explore the expression pattern of the LYVE-1 protein
in more detail, we generated a polyclonal serum by immu-
nizing rabbits with purified LYVE-1 Fc fusion protein (see
above). The serum was then preabsorbed on human IgG
Sepharose to remove contaminating Fc-reactive antibod-
ies, followed by affinity chromatography on a LYVE-
1ÐSepharose column. The specificity of the purified antise-
rum was established using immobilized LYVE-1 Fc fusion
protein in an ELISA assay. As shown in the top panel of
Fig. 7, the LYVE-1 antiserum was highly specific for
LYVE-1 Fc at dilutions below 1:100 and reacted only
Figure 4. LYVE-1 binds both immo-
bilized and soluble HA. LYVE-1, ex-
pressed as a soluble IgFc fusion pro-
tein in transiently transfected human
COS fibroblasts, was compared with
CD44 for binding to HA and other
glycosaminoglycans. A shows LYVE-1
and CD44H Fc fusion proteins iso-
lated from the supernatants of [35S]
methionine/cysteine-labeled transfec-
tants and electrophoresed on a 7.5%
polyacrylamide SDS-PAGE gel. Sam-
ples were the protein AÐSepharose
adsorbed proteins from control un-
transfected cells (lane 1), CD44H
Fc transfected cells (lane 2), and
LYVE-1 transfected cells (lane 3).
The LYVE-1 fusion protein com-
prises residues 1Ð232 of the extracel-
lular domain fused to the hinge (H),
CH2, and CH3 domains of human
IgG1. Details of the CD44H Fc pro-
tein, which includes residues 1Ð200 of
the extracellular domain, have been
published previously (1). For ligand
binding assays, LYVE-1 Fc was com-
pared with CD44H Fc and the nega-
tive control fusion proteins CD33 Fc
and ICAM-2 Fc for adhesion to im-
mobilized and soluble HA in 96-well
microtiter plates (see Materials and
Methods). B shows binding of the fu-
sion proteins to immobilized HA, in
the absence of competing glycosami-
noglycans; C shows binding (LYVE-1
Fc only) in the presence of free chon-
droitin-4-SO4, chondroitin-6-SO4, or
heparin; and D shows binding to solu-
ble biotinylated HA. Detection of
bound fusion protein and biotin-
ylated HA was carried out using per-
oxidase-conjugated antiÐhuman IgFc
antibody and peroxidase-conjugated
streptavidin, respectively. Values are
the mean 6 SEM of at least three rep-
licates.The Journal of Cell Biology, Volume 144, 1999 796
weakly with the control ICAM-2 fusion protein, which in
common with LYVE-1 Fc, contains the hinge, CH2, and
CH3 domains of human IgG1. Importantly, the LYVE-1
antiserum was unreactive with a CD44H ectodomain con-
struct CD44158his which contains a functional Link module
(residues 1Ð158) expressed as a histidine-tagged bacterial
fusion protein (3), with CD44H Fc and with CD44-trans-
fected COS 1 cells (not shown). Finally, the LYVE-1 anti-
serum (1:100 dilution) had the capacity to completely
block binding of soluble bHA (Fig. 7, bottom). These data
indicate the polyclonal serum is specific for LYVE-1 and
does not exhibit reactivity with CD44, its closest homo-
logue.
Immunoperoxidase staining of human tissues with the
polyclonal LYVE-1 serum revealed an unusual and highly
restricted expression pattern, as shown in Fig. 8 and sum-
marized in Table I. Intriguingly the expression of LYVE-1
was mostly confined to endothelial cells lining vessels of
Figure 5. Northern blot hybridization analysis of LYVE-1 recep-
tor mRNA. RNA blots containing 2 mg poly(A)1 RNA per lane
from each of the tissues shown were hybridized to a 32P-labeled
full-length LYVE-1 DNA probe (top), or glyceraldehyde-3-phos-
phate dehydrogenase probe (bottom), and washed at high strin-
gency before autoradiography (see Materials and Methods). The
migration positions of RNA calibration markers (kilodaltons)
are shown to the left of the figure.
Figure 6. RT-PCR analysis of LYVE-1 mRNA
expression in tissue culture cell lines. LYVE-1
and CD44 mRNA levels were compared within a
panel of tissue culture cell lines representing dif-
ferent lineages. Samples of cDNA prepared
from each of the cell lines shown were amplified
with primers specific for either LYVE-1 (top),
CD44 (middle), or glyceraldehyde-3-phosphate
dehydrogenase (control, bottom) followed by
electrophoresis on 1.25% agarose gels, staining
with ethidium bromide (glyceraldehyde-3-phos-
phate dehydrogenase only), or Southern blotting
and hybridization with the appropriate 32P-
labeled detection oligonucleotides as described
in Materials and Methods. Arrows depict the
sizes of the PCR products in each case.
Figure 7. Specificity of a
LYVE-1 receptor polyclonal
serum. The specificity of an
affinity-purified rabbit poly-
clonal antiserum generated
against soluble LYVE-1 re-
ceptor and its capacity to
block HA binding were as-
sessed in microtiter plate
binding assays. In the top
panel, wells coated with ei-
ther LYVE-1 Fc (filled cir-
cles), the CD44H ectodo-
main fragment CD44158his
(triangles), or the control fu-
sion protein ICAM-2 Fc
(squares) were incubated
with appropriately diluted
LYVE-1 specific polyclonal
antiserum, and binding was
detected with peroxidase-
conjugated antiÐhuman Ig
(see Materials and Methods).
As a control, a second set of LYVE-1Ðcoated wells was reacted
with appropriately diluted preimmune serum (open circles). In
the bottom panel, wells coated with LYVE-1 Fc were incubated
with soluble biotinylated HA (5 mg/ml), in the presence of in-
creasing concentrations of either LYVE-1 antiserum or control
preimmune serum followed by detection of bound HA as de-
scribed in Materials and Methods. Data in each case are the
mean  6 SEM of triplicate determinations.Banerji et al. Lymph Vessel Hyaluronan Receptor 797
comparison of the two vessel types in sections of salivary
gland (Fig. 8 g), where blood vessels that are clearly distin-
guishable by their erythrocyte content (visible through
weak nonspecific staining with rabbit IgG) are negative for
LYVE-1, while the adjacent empty lymph vessels stain in-
tensely. This distinction was confirmed by double immu-
nofluorescence staining of small intestine sections (Fig. 9)
with antibodies to LYVE-1 and to the vascular endothelial
markers CD34 (sgp90) and vWF (Factor VIIIÐrelated
molecule). LYVE-1 staining was mutually exclusive with
both of the other markers, and was confined to irregularly
shaped vessels within the submucosae that were devoid of
erythrocytes. Furthermore, double immunofluorescence
staining revealed little or no CD44 expression on lym-
phatic vessels, indicating that LYVE-1 is likely to be
the major receptor for HA on lymphatic endothelial cells
(Fig. 9). 
Physiological Function of the LYVE-1 HA Receptor
The lymphatic system is the main conduit for transport of
HA from the tissues and degradation within lymph nodes.
However, the molecules within lymphatic vessels which in-
teract with lymph fluid HA have not been identified, and
the mechanisms driving HA transport to the lymph nodes
have yet to be elucidated. Therefore, we considered the
possibilities that LYVE-1 might either sequester HA on
Figure 8. Localization of the LYVE-1 HA receptor in human tissues. Paraffin-embedded human tissue sections were stained with rab-
bit polyclonal LYVE-1 antiserum (1:100 dilution), followed by peroxidase-conjugated goat antiÐrabbit IgG as described in Materials
and Methods. Tissues shown are colon (a and b), small intestine (cÐf), salivary gland (g), skin (h and i), lymph node (j), spleen (k), and
tonsil (l). m shows cultured HUVEC stained with LYVE-1 and FITC-conjugated antiÐrabbit Ig (see Materials and Methods). Bars, j
and l, 500 mm; a, c, and eÐh, 200 mm; b, d, and k, 50 mm; and i and m, 20 mm. Black arrows depict lymphatic vessels, both empty (dÐg)
and containing lymphocytes (b), and red arrows depict blood vessels clearly identified by their content of weakly stained erythrocytes (g
and i).
the lymphatic system. The only other sites of prominent
LYVE-1 expression were sinusoidal endothelial cells within
the spleen and placental syncytiotrophoblasts (Table I and
Fig. 8 k). In contrast with the expression pattern of CD44,
no LYVE-1 was detected on lymphocytes or other he-
matopoietic cells within lymphoid organs such as the tonsil
and thymus (Table I and Fig. 8 l). Localization of LYVE-1
within the lymphatics was most strikingly visible among
the draining lymphatic vessels within the submucosae, un-
derlying the intestinal crypts in colon and small intestine
(Fig. 8, aÐd). Many small lymph vessels, including some
containing large numbers of lymphocytes, showed intense
endothelial staining. High levels of LYVE-1 expression
were also apparent on the lacteal vessels draining individ-
ual intestinal villi, on subdermal lymphatic vessels within
the skin, and on lymphatic vessels within peripheral nodes
(Fig. 8, eÐj). A similar expression pattern was found in
other tissues displaying prominent lymphatics, particularly
the appendix and stomach (see Table I). In contrast, no
LYVE-1 was detected on blood vessels within any of the
tissues tested. Interestingly, LYVE-1 protein expression
was detected on the surface of cultured HUVEC (Fig. 8
m), confirming the detection of LYVE-1 mRNA by RT-
PCR (see above). This is most likely to be the result of cul-
ture induced de-differentiation as no vascular staining was
observed in tissue sections of umbilical vein (not shown).
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the lymph vessel wall or promote HA-mediated rolling of
leukocytes present within the lymph fluid. In the first in-
stance, we looked for an association between LYVE-1 and
its ligand HA on the luminal face of tissue lymphatics by
double immunofluorescent staining, using bHABC com-
posed of bovine Aggrecan and Link protein (Fig. 9).
Abundant quantities of HA were detected throughout the
parenchyma and lining the walls of numerous vessels in all
the tissues tested (data not shown). A significant amount
of this HA indeed colocalized with LYVE-1 in numerous
patches (visible as yellow staining), around the luminal
surface of lymph vessels, particularly those in the small in-
testines (Fig. 9). Although relatively high levels of HA (50
mg/ml) are normally found within lymph vessels in vivo
(49), we observed some variation in the amounts retained
on LYVE-1 stained vessels between and within different
tissues. It is not yet clear whether this reflects variation in
the amount of HA, or its recovery during the preparation
of different tissues, or variation in the binding affinity of
LYVE-1 in different locations.
Finally, we looked for evidence that leukocytes adhere
to HA presented by LYVE-1 present on the lymph vessel
wall. Our initial attempts to demonstrate such adhesion
using CD44 transfected Namalwa B lymphoma cells and
frozen sections of gut lymphatics in Stamper-Woodruff
type assays were difficult to interpret, because of the high
levels of binding to HA within the surrounding paren-
chyma (not shown). As an alternative, we tested the ability
of LYVE-1 Fc immobilized on plastic microtiter dishes to
support HA-mediated binding to CD44. As shown in Fig.
10, LYVE-1 indeed supported HA-mediated binding of
CD44, regardless of the order used for primary presenta-
tion or secondary HA binding. In conclusion, our results
indicate that LYVE-1, in addition to binding HA within
the lymphatics, may also bind HA-coated lymphocytes in
transit to the lymph nodes.
Discussion
The interaction between cells and extracellular matrix HA
is clearly of fundamental importance both during embry-
onic limb development and in processes such as wound
healing and inflammation in later adult life (19Ð22). Such
importance predicts that many receptors must be involved
in HA adhesion, and that complex mechanisms must exist
to regulate both their expression and their ligand-binding
affinity. Yet at present, the list of professional cell surface
HA receptors is small and includes only the CD44 mole-
cule, RHAMM, and the LEC HA receptors. Furthermore,
deletion of the gene for CD44, the most abundant and
widely expressed of these, has little if any deleterious ef-
fects on the embryo (43). Thus, it has become increasingly
clear to many workers in the field that additional receptors
for HA are likely to exist within the genome.
In this paper we have described the primary structure
and biological function of one such receptor, termed
LYVE-1, which is present within vessels of the lymphatic
system. This new receptor is a type I integral membrane
polypeptide whose extracellular domain encodes a single
cartilage Link module, the prototypic HA-binding domain
conserved within all members of the Link or hyaladherin
superfamily (51). The central core of the LYVE-1 Link
module (C2-C3) is 57% identical to that of the human
CD44 HA receptor, the only other Link superfamily HA
receptor to be described to date and the closest homologue
of LYVE-1. Nevertheless, there are distinct differences be-
tween LYVE-1 and CD44 that suggest the two homo-
logues differ either in the mode of HA binding or in its
regulation.
Firstly, in terms of HA binding, only three of nine resi-
dues identified as essential within the CD44 Link module
are conserved in LYVE-1 (Lys 38, Tyr 79, and Asp 100)
and none of the downstream COOH-terminal basic resi-
dues of CD44 are present. Furthermore, unlike CD44, the
affinity of LYVE-1 for bHA is drastically reduced with in-
creasing degrees of biotinylation. These features suggest
HA is orientated differently within the LYVE-1 Link
module and suggest it may bind a larger HA unit than the
minimal HA6 unit bound by CD44 (18, 55). Competition
experiments with defined HA fragment sizes will be re-
Table I. Tissue Distribution of the LYVE-1 Molecule
Tissue type* Staining intensity and descriptionà
Hematopoietic
Lymph node 11 Lymphatic vessels
Spleen 11 Sinusoidal cells
Tonsil 2
PBMC 2
Endocrine
Adrenal 1 Zona reticularis cells
Breast 11 Lymphatic vessels
Pancreas 1 Exocrine cells/islets of Langerhans
Thryroid 1
Prostate 2
Salivary gland 1 Lymphatic vessels
Reproductive
Cervix 2
Ovary 2
Placenta 1 Syncytiotrophoblasts
Testis 2
Uterus 1/2
Gastrointestinal
Appendix 1 Lymphatic vessels
Colon 11 Lymphatic vessels
Omentum 1 Lymphatic vessels
Small intestine 11 Lymphatic vessels
Stomach 1 Lymphatic vessels
Cardiorespiratory
Heart 2
Lung 1/2 Lymphatic vessels
Other
Brain 1 Cerebral cortex neurons
Cerebellum 2
Bone marrow 1
Bladder 2
Kidney 11 Tubular cuboidal epithelium
Liver 1/2
Skin 1 Lymphatic vessels
àParaffin-embedded human tissue sections were incubated with a polyclonal rabbit
antiÐhuman LYVE-1 protein antiserum and stained with horseradish peroxidaseÐcon-
jugated antiÐrabbit antibody as described in Materials and Methods (see also Fig. 8).
*Staining intensity was assessed semiquantitatively using the following indices:
111, strong staining; 11, moderate staining; 1, weak staining; 1/2, equivocal
staining; 2, no staining.
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quired to distinguish between these possibilities. A further
distinction between LYVE-1 and CD44 is their dramatic
difference in substrate specificity. Unlike CD44, LYVE-1
displays exquisite specificity for binding HA and no af-
finity for the glycosaminoglycans chondroitin-4 sulfate,
chondroitin-6 sulfate, or heparan sulfate. This remark-
able ligand specificity also distinguishes LYVE-1 from the
lymph node HA receptors which mediate the uptake and
degradation of HA from afferent lymph, a process that is
blocked by chondroitin sulfate and chondroitin sulfate
proteoglycans (54).
Secondly, the regulation of HA binding and its func-
tional consequences are likely to differ significantly from
CD44. Excluding the Link domain and its immediate
boundaries, the LYVE-1 extracellular domain, transmem-
brane anchor, and cytoplasmic tail bear no similarity to
those of the CD44 molecule. In the CD44 ectodomain, al-
ternative splicing of up to 10 exons within the membrane-
proximal region regulates HA binding in some cell types
(5, 44), and introduces new ligand-binding specificities (4,
17). Although we have detected high molecular weight
LYVE-1 transcripts in some tissues by Northern blotting
(see Fig. 5), we have so far not observed alternatively
spliced variants by RT-PCR. In the CD44 transmembrane
anchor, a central cysteine residue (30) regulates HA bind-
ing in a cell-specific manner, through the formation of
lipid domains within the bilayer (35, 39). No such residue
is present in the LYVE-1 transmembrane anchor. Lastly,
in the CD44 molecule, the 71-residue cytoplasmic tail
binds the cytoskeletal components ankyrin and ezrin (52),
and is subject to serine phosphorylation that regulates cell
motility on HA substrata (16, 38). Although the lack of se-
quence conservation does not rule out the possibility that
LYVE-1 interacts with these cytoskeletal components via
different residues or that the LYVE-1 cytoplasmic tail in-
teracts with other as yet undefined molecules, it seems un-
likely that the mechanisms which regulate CD44-HA in-
teractions are duplicated for LYVE-1, its closest known
homologue.
Perhaps the most striking distinction between LYVE-1
Figure 10. LYVE-1 molecules support HA-mediated binding to
CD44. The capacity of LYVE-1 and CD44 to form ternary com-
plexes with HA was tested using a modification of the HA-bind-
ing assay in Fig. 4 B. A shows binding of LYVE-1 Fc and CD33
Fc (control) to HA, presented by immobilized CD44158his protein.
B shows binding of CD44 Fc to HA, presented by immobilized
LYVE-1 Fc or CD33 Fc (control). Bound fusion proteins were
detected with peroxidase-conjugated antiÐhuman IgFc antibody,
or with peroxidase-conjugated CD44 mAb A3D8, respectively,
as described in Materials and Methods. No binding was observed
in the absence of HA (not shown). Data are the mean 6 SEM
(n 5 3).
Figure 9. Immunofluorescent
staining of LYVE-1 in lymphatic
vessels and colocalization with
HA. Sections of human small in-
testine were double stained for
LYVE-1, CD44, the vascular en-
dothelial molecules CD34 and
vWF, and for HA, by indirect
immunofluorescence micros-
copy, using Texas red or fluores-
cein-conjugated secondary anti-
bodies or bHABC as described
in Materials and Methods. The
antibody combinations were as
follows: A, LYVE-1 (red) and
CD34 (green); B, LYVE-1 (red)
and vWF (green); C, LYVE-1
(red) and CD44 (green); and D
and E, LYVE-1 (red) and
bHABC (green). Arrows depict
small blood vessels containing
erythrocytes (pale yellow/
green), which are LYVE-1-ve.
Lymph vessel endothelium posi-
tive for both LYVE-1 and HA
in D and E is stained yellow/or-
ange. Bar, 50 mm.The Journal of Cell Biology, Volume 144, 1999 800
and CD44 is in their patterns of tissue expression. Intrigu-
ingly, the LYVE-1 molecule is largely if not exclusively re-
stricted to lymph vessel endothelial cells from which CD44
is almost completely absent. Comprehensive analyses of a
large panel of human tissues by immunoperoxidase stain-
ing with specific antisera revealed LYVE-1 lining the lym-
phatics in virtually every tissue where these structures
could be distinguished, and included vessels draining gas-
trointestinal tissues, skin, lymph nodes, breast, and sali-
vary gland. The greatest concentration of LYVE-1 expres-
sion was seen in submucosal lymph vessels underlying
smooth muscle in the colon, and the Lacteal vessels of in-
testinal villi that transport dietary lipid absorbed from the
small intestine. Lymphatic vessels are morphologically dis-
tinguishable from blood vessels by their reduced or miss-
ing basement membrane and lack of erythrocyte content.
There are currently no specific immunochemical markers
that allow identification of lymphatics, although limited
studies with endothelial markers indicate differential ex-
pression of the L-selectin ligand CD34 and the coagulation
Factor VIIIÐrelated protein vWF (32, 42). Our own results
using double immunofluorescence indicate that LYVE-1
defines a set of lymphatic vessels which express neither
CD34 nor vWF and identify LYVE-1 as a powerful new
marker for future studies of lymphatic structure and func-
tion.
The absence of LYVE-1 from vascular endothelial cells,
in addition to its absence from lymphocytes, macrophages,
fibroblasts, and epithelial cells, implies a rather different
physiological role from that of the CD44 molecule, which
is expressed abundantly in each of these locations (41) but
is largely absent from lymphatic vessels. The primary role
of the CD44 HA receptor appears to be the regulation of
cell motility (50), as evidenced by its association with the
migration of mesenchymal cells during differentiation, and
with the hematogenous spread of tumor cells in experi-
mental neoplasia (47). This is also apparent in inflamma-
tion, where CD44 expression on lymphocytes promotes
migration through HA-coated vascular endothelium (7, 8),
as well as the migration of lymphocytes through HA-
coated reticular networks within peripheral lymph nodes
(6). LYVE-1 by contrast appears to be restricted to rel-
atively nonmotile lymphatic endothelial cells, where it
seems more likely to function in the immobilization of HA
in the vessel lumen, rather than in its recognition as a posi-
tional cue for migration.
A prominent function of the lymphatic system is the
provision of fluid drainage of immune cells and foreign an-
tigens from the tissues to the peripheral lymph nodes,
where the latter are sampled by professional antigen-pre-
senting cells and phagocytes. Lymph fluid contains high
levels (40Ð50 mg/ml) of HA (see ref. 12 and reviewed in
ref. 10), and its flux through the lymphatics is known to in-
crease in inflammatory diseases such as rheumatoid arthri-
tis and psoriasis and in response to bacterial infection (10,
27). The lymph vessels thus act as a conduit both for mi-
grating inflammatory cells and for HA, although the pre-
cise relationship between the two is not clear. One possi-
bility is that LYVE-1 functions as an endocytic receptor in
an analogous fashion to CD44 on macrophages and the
LEC HA receptors on liver endothelium. The specificity
of LYVE-1 for HA does, however, appear to rule out any
likelihood that it is the receptor involved in HA uptake
and degradation within the lymph node. Alternatively,
since inflammatory cells express CD44, we are tempted to
speculate that LYVE-1 molecules may promote their ad-
hesion to lymphatic endothelium via HA. Such a role is
supported by our finding that LYVE-1 and HA colocalize
to the luminal face of the lymph vessels, and that LYVE-1
can support HA-mediated adhesion to CD44. We are
currently performing experiments to distinguish between
these and other interesting possibilities.
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